Gemcitabine
Product Images NDC 72485-222

7 FDA label images from Armas Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gemcitabine (NDC 72485-222). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image01)

Structural Formula (Image01)
Chemical structure of Gemcitabine hydrochloride showing its nucleoside analogue framework with hydroxyl, amino, and fluorine groups, including the pyrimidine ring and hydrochloride (HCl) component.*
FDA Label Image

Figure 1 (Image02)

Figure 1 (Image02)
A Kaplan-Meier survival curve comparing progression-free survival probabilities over months for two groups: Gemcitabine/Carboplatin (N=178) and Carboplatin alone (N=178). The graph shows progression-free probability on the y-axis and progression-free survival in months on the x-axis, highlighting longer median progression-free survival for the combination therapy (8.6 months) versus Carboplatin alone (5.8 months) with a log-rank p-value of 0.0038.*
FDA Label Image

Figure 2 (Image03)

Figure 2 (Image03)
A Kaplan-Meier curve chart showing progression-free probability over time (months) comparing Gemcitabine/Paclitaxel and Paclitaxel alone. The median time to documented disease progression is 5.2 months for Gemcitabine/Paclitaxel (N=178) and 2.9 months for Paclitaxel (N=262). The logrank p-value is less than 0.0001.*
FDA Label Image

Figure 3 (Image04)

Figure 3 (Image04)
A survival curve graph comparing survival probability over time in months for Gemcitabine/Cisplatin (N=260) versus Cisplatin (N=262). The graph shows median survival of 9.0 months for Gemcitabine/Cisplatin and 7.6 months for Cisplatin. One-year survival rates and statistical test values (Logrank and Wilcoxon p-values) are included.*
FDA Label Image

Figure 4 (Image05)

Figure 4 (Image05)
A survival curve chart comparing the fraction surviving over time (in months) between Gemcitabine and 5-FU. The y-axis represents the fraction surviving from 0.0 to 1.0, and the x-axis represents survival time in months from 0 to 20. The Gemcitabine curve shows a slower decline in survival compared to the 5-FU curve.*
FDA Label Image

Label1 (Image06)

Label1 (Image06)
Label for Gemcitabine Injection by Armas Pharmaceuticals Inc., showing 1 g/26.3 mL (38 mg/mL) strength in a single-dose vial. The label states it is for intravenous infusion only and must be diluted before use. It includes storage instructions, manufacturer Shilpa Medicare Limited, and distributor information for Armas Pharmaceuticals. A caution note indicates the product is a cytotoxic agent.*
FDA Label Image

Label2 (Image7)

Label2 (Image7)
Outer carton label for Gemcitabine Injection 1 g/26.3 mL (38 mg/mL) for intravenous infusion. The carton specifies a 26.3 mL single-dose vial, with instructions to store at 2 to 8°C and to discard unused portion. Manufactured by Shilpa Medicare Limited, India, and distributed by Armas Pharmaceuticals Inc. The carton includes warnings about cytotoxicity and storage, plus NDC 72485-222-10.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.